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474Objective: Adenosine A2A receptor activation potently attenuates lung ischemia–reperfusion injury. This study
tests the hypothesis that adenosine A2A receptor activation attenuates ischemia–reperfusion injury by inhibiting
CD4þT cell activation and subsequent neutrophil infiltration.
Methods: An in vivo model of lung ischemia–reperfusion injury was used. C57BL/6 mice were assigned to either
sham group (left thoracotomy) or 7 study groups that underwent ischemia–reperfusion (1 hour of left hilar occlu-
sion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 min-
utes before reperfusion with or without antibody depletion of neutrophils or CD4þT cells. After reperfusion, the
following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by
immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar la-
vage fluid, lung wet/dry weight, and microvascular permeability.
Results: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeabil-
ity after ischemia–reperfusion compared with control. Immunohistochemistry and myeloperoxidase content dem-
onstrated significantly reduced infiltration of neutrophils and CD4þ T cells after ischemia–reperfusion in
ATL313-treated mice. Although CD4þ T cell–depleted and neutrophil-depleted mice displayed significantly
reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression
of tumor necrosis factor-a, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory
protein-1, and RANTES were significantly reduced in neutrophil- and CD4þT cell–depleted mice and reduced
further by ATL313 only in neutrophil-depleted mice.
Conclusions: These results demonstrate that CD4þT cells play a key role in mediating lung inflammation after
ischemia–reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine
A2A receptors on CD4þT cells and neutrophils. (J Thorac Cardiovasc Surg 2010;139:474-82)Ischemia–reperfusion (IR) injury entails enhanced inflam-
matory responses during reperfusion and remains a major
cause of respiratory failure and other complications after
lung transplantation.1 We2-4 have previously shown that pul-
monary macrophages and neutrophils contribute impor-
tantly to lung IR injury, with macrophages serving as
triggers and neutrophils as end effectors of tissue injury. Al-
veolar epithelial cells also interact with alveolar macro-
phages to augment the inflammatory response after IR.5
Although recent studies suggest that lymphocytes may
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The Journal of Thoracic and Cardiovascular Surgof specific subtypes of lymphocytes and their cross-talk
with macrophages and neutrophils in the context of lung
IR injury remain to be elucidated.
Multiple lines of evidence suggest that the adenosine A2A
receptor (A2AAR) is critical for adenosine-mediated protec-
tion from IR injury. A2AAR-mediated inhibition of IR injury
has been documented in various organ systems including
liver, lung, kidney, and heart8-11; however, the precise mech-
anisms responsible for A2AAR-mediated protection remain
unknown. A2AARs are predominantly expressed on leuko-
cyte populations and mediate a variety of physiologic re-
sponses. A2AARs couple to G proteins and activate
adenylyl cyclase leading to increased cellular levels of cyclic
adenosine monophosphate.12,13 The mechanisms of protec-
tion mediated by A2AAR activation may include inhibition
of leukocyte-mediated inflammatory responses,13 vasodila-
tion,14 and direct effects on organ parenchymal cells.12
We11 have previously demonstrated a T lymphocyte–medi-
ated mechanism for A2AAR activation after myocardial IR in
mice.
Our previous studies have shown that administration of
a selective A2AAR agonist during reperfusion significantly
reduces lung and heart IR injury in both in vivo and ex
vivo animal models.8,11,15 In a recent study, we16 haveery c February 2010
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Xalso demonstrated a key role of CD4þT cells in the initiation
and progression of lung IR injury and that activation of
CD4þT cells lies upstream of neutrophil activation and in-
filtration. Although in vivo experiments have demonstrated
the protective effect of A2AAR activation, these experiments
have not identified the major cellular target(s) responsible
for the salutary effects of A2AAR activation in lung IR in-
jury. In the present study, we used a potent and selective
A2AAR agonist, ATL313, in an in vivo mouse model of
lung IR injury. By using specific antibodies to deplete
CD4þ T cells or neutrophils, we demonstrate a primary
role of A2AAR activation on CD4þT lymphocytes in pro-
tecting the lung against IR injury.
MATERIALS AND METHODS
Study Design
This study used 8- to 12-week-old, male C57BL/6 mice (Jackson Labo-
ratory, Bar Harbor, Maine), which were assigned to a sham group or 1 of 7
experimental groups that underwent IR (1 hour of left lung ischemia fol-
lowed by 2 hours of reperfusion). The duration of 1 hour of ischemia and
2 hours of reperfusion was chosen on the basis of our previous study, which
determined that this time frame resulted in maximum pulmonary dysfunc-
tion after ischemia.16 A total of 8 groups were used in the current study
(n ¼ 5–9/group), which are summarized as follows: (1) sham (sham thora-
cotomy with no ischemia); (2) IR (1 hour of ischemia followed by 2 hours of
reperfusion); (3) IRþATL313 (mice undergoing IR with treatment of
ATL313 during reperfusion), (4) immunoglobulin G (IgG) (mice pretreated
with control IgG antibodies that undergo IR); (5) neutrophil depletion (neu-
trophil-depleted mice that undergo IR); (6) neutrophil depletionþATL313
(same as group 5 with treatment of ATL313 during reperfusion); (7)
CD4þT cell depletion (CD4þT cell–depleted mice that undergo IR); and
(8) CD4þ T cell depletionþATL313 (same as group 7 with treatment of
ATL313 during reperfusion). Note that all groups underwent left lung IR ex-
cept the sham group. The A2AAR agonist, ATL313 (gift of Adenosine Ther-
apeutics, LLC, Charlottesville, Va), was administered via intravenous
injection at a dose of 3 mg/kg 5 minutes before reperfusion. This dose
was based on previous studies that have shown that 3 mg/kg ATL313 po-
tently attenuates IR injury without significant hemodynamic effects.8 This
study was performed concurrently with a previously reported study,16 and
thus much of the data from the antibody-treated, control groups of animals
in the current study (IgG, neutrophil depleted, and CD4 depleted) wereThe Journal of Thoracic and Cashared with the previous study. This study conformed to the ‘‘Guide for
the Care and Use of Laboratory Animals’’ published by the National Insti-
tutes of Health (NIH publication No. 85-23, revised 1985) and was con-
ducted under protocols approved by the University of Virginia’s
Institutional Animal Care and Use Committee.
Hemodynamic Study
The effect of ATL313 or vehicle (saline) on hemodynamics was evalu-
ated in C57BL/6 mice. Mice were anesthetized with 1% (vol) isoflurane.
The right common carotid artery was exposed and cannulated with a 1.4F
Millar Mikro-Tip catheter (Millar Instruments, Inc, Houston, Tex). After
peripheral arterial blood pressures were acquired, the catheter tip was
advanced into the left ventricular (LV) chamber. After bolus injection of
3 mg/kg ATL313 or saline (2 mL/g) via the left external jugular vein, LV
pressures (end-systolic and end-diastolic pressures), positive and negative
developed pressures, as well as aortic arterial pressure were continuously
recorded for 30 minutes.
Depletion of Neutrophils and T lymphocytes
Depletion of neutrophils and CD4þ T cells was achieved by using
selective antibodies as described previously.16 Rat anti-Gr-1 monoclonal
antibody was used to deplete neutrophils. In brief, 10 mg anti-Gr-1
monoclonal antibody (eBioscience, San Diego, Calif) was injected via tail
vein 24 hours before undergoing study. To deplete CD4þ T cells, anti-
CD4 monoclonal antibody (GK1.5, eBioscience) was injected intraperito-
neally on 2 consecutive days at a dose of 0.2 mg per mouse per day. Two
days after the second injection, these animals were studied. We11 have pre-
viously documented specific depletion of CD4þT cells by anti-CD4 mono-
clonal antibodies in mice by flow cytometry of peripheral blood and spleen
cells. Perioperatively, blood (30–40 mL) was obtained by puncturing the left
external jugular vein. Circulating blood leukocyte counts were performed
with a HemaVet Hematology System (CDC Technologies, Oxford, Conn).
In Vivo Model of Lung IR
An in vivo hilar clamp model of IR was used as previously described.16
Mice undergoing IR were subjected to 1 hour of ischemia (left lung hilar
occlusion) followed by 2 hours of reperfusion. In brief, mice were anesthe-
tized with inhalation isoflurane, intubated with PE-60 tubing, and connected
to a pressure-controlled ventilator (Harvard Apparatus Co, South Natick,
Mass). Mechanical ventilation with room air was set at 150 strokes/min,
1.0 mL stroke volume, and peak inspiratory pressure less than 20 cm
H2O. Heparin (20 U/kg) was given via external jugular injection to mini-
mize thrombosis in the pulmonary vasculature during ischemia. A left tho-
racotomy was performed by cutting the left fourth rib, and the left hilum was
exposed. A 6-0 Prolene polypropylene suture (Ethicon, Inc, Somerville, NJ)
was placed around the left hilum facilitated by a tip-curved (22-gauge)
gavage needle. Both ends of the suture were threaded through a 5-mm
long PE-50 tube. Hilar occlusion was achieved by pulling up on the suture
and thus pressing the tube against the hilum to initiate ischemia. A small sur-
gical clip was applied to the suture above the tube to maintain tension
against the hilum. The thoracotomy was then suture-closed and the mouse
was extubated and allowed to recover during the 1-hour hilar occlusion
period. The average time on the ventilator for each animal was 10 minutes.
Five minutes before reperfusion, the mouse was reanesthetized and reintu-
bated. Reperfusion was achieved by removing the clip, tube, and suture.
Again, the chest was suture-closed. The mouse was extubated and placed
back in the cage during the 2-hour reperfusion period. Temperature was
monitored during surgery by an anal probe and maintained between
36.5C and 37.5C. Sham animals received only thoracotomy without hilar
occlusion. Cessation of blood flow during ischemia was confirmed in sepa-
rate mice using Evans blue dye (Sigma–Aldrich, St Louis, Mo), which was
injected intravenously immediately after hilar clamping, and the left lungs
were harvested 1 hour later. We consistently found no detectable levels of
Evans blue dye in these lungs, thereby confirming ischemia.rdiovascular Surgery c Volume 139, Number 2 475
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At the end of scheduled reperfusion, pulmonary function was evaluated
with the use of an isolated, buffer-perfused mouse lung system (Hugo Sachs
Elektronik, March-Huggstetten, Germany) as previously described.16 Once
properly perfused and ventilated, the isolated lungs were maintained on the
system for a 5-minute equilibration period before data were recorded for an
additional 10 minutes. Hemodynamic and pulmonary parameters were
recorded by the PULMODYN data acquisition system (Hugo Sachs Elek-
tronik). The values during the 10-minute data acquisition period remained
very constant in all animals, and the pulmonary function data reported in
this study reflect the final values at the end of this period.
Bronchoalveolar Lavage (BAL)
After pulmonary function measurement, left lungs were lavaged with 0.4
mL of phosphate-buffered saline solution. The BAL fluid was centrifuged at
4C (500g, 5 minutes), and the supernatant was collected and stored at
80C until further analysis.
Lung Wet/Dry Weight Ratio
In separate groups of animals (n¼ 5/group), the left lung was harvested,
weighed, and then placed in a vacuum oven (at 54C) until a stable dry weight
was achieved. The lung wet weight/dry weight ratio was then calculated.Pulmonary Microvascular Permeability
In separate groups of animals (n ¼ 5/group), lung microvascular perme-
ability was estimated by the Evans blue dye extravasation technique,16,17
which is an index of change in protein permeability. Evans blue dye (20
mg/kg) was injected intravenously 30 minutes before the animals were
humanely killed. The pulmonary vasculature was then perfused for 10
minutes with phosphate-buffered saline to remove intravascular dye. Lungs
were then homogenized in phosphate-buffered saline to extract the Evans
blue and centrifuged. The absorption of Evans blue was measured in the
supernatant at 620 nm and corrected for the presence of heme pigments:
A620 (corrected) ¼ A620 (1.426 3 A740þ 0.030). The concentration of
Evans blue was determined according to a standard curve and expressed
as microgram/gram wet lung weight.
Immunohistochemistry of Pulmonary CD4þT Cells
Lung tissue was fixed with 1% paraformaldehyde at 4C for 24 hours
and then embedded in Tissue-Tek O.C.T compound (Sakura, Torrance,
Calif) before storage at 80C. Immunostaining was performed with rat
anti-mouse CD4 antibody (GK1.5) (Santa Cruz Biotechnology, Santa
Cruz, Calif) using a Vectastain ABC kit (Vector Laboratories, Burlingame,
Calif) as described previously.16
Measurement of Myeloperoxidase (MPO)
MPO levels were measured in BAL fluid using a commercially available
mouse MPO enzyme-linked immunosorbent assay kit (Cell Sciences,
Canton, Mass).
Measurement of Cytokines/Chemokines
Cytokine and chemokine protein levels in BAL fluid were quantified by
the Bioplex Bead Array technique with a multiplex cytokine panel assay
(Bio-Rad Laboratories, Hercules, Calif) as described previously.5,16
Statistical Analysis
Mean values for each group are plotted in the accompanying figures,
along with bars indicating the standard error of mean. Tests of the statistical
significance of the observed differences in mean values between groups
were assessed by 1-way analysis of variance and the Satterthwaite T test,
which provides an adjustment for unequal variance between groups.476 The Journal of Thoracic and Cardiovascular SurgRESULTS
Effect of ATL313 on Hemodynamics
Potential changes in hemodynamics were assessed after
administration of ATL313 (3 mg/kg) or vehicle (saline)
(n ¼ 4/group). Heart rate and mean arterial pressure re-
mained stable in vehicle-treated mice. There was a small
but insignificant increase in heart rate of approximately
14% in ATL313-treated mice compared with vehicle treat-
ment during the first 25 minutes (Figure 1, A). There was
a small but insignificant decrease (<20%) in mean arterial
blood pressure after ATL313 administration that returned
to baseline level within 10 minutes (Figure 1, B). LV pres-
sures and LV developed pressures had a similar pattern of
changes as arterial pressures (data not shown).Effect of ATL313 on Blood Cell Counts
Blood was sampled for complete counts of circulating
leukocytes before surgery and 2 hours after sham thoracot-
omy (sham group) or at the end of IR (IR or ATL313-treated
IR animals) (n¼ 5/group). The percent change in cell counts
measured after reperfusion versus cell counts before ische-
mia (baseline) is shown (Figure 1, C). All preoperative
and postreperfusion measurements were performed on the
same mouse to eliminate animal-to-animal variability. The
numbers of preoperative, circulating white blood cells
(WBCs) (baseline ¼ 4333  799 cells/mL), neutrophils
(baseline ¼ 330  83 cells/mL), lymphocytes (baseline ¼
3642  675 cells/mL), and monocytes (baseline ¼ 368  1
16 cells/mL) did not significantly change after sham thora-
cotomy. In the IR group, IR had no effect on WBC counts
but caused a significant increase in neutrophils by 3.5-fold
and a significant decrease in lymphocytes by 57% when
compared with corresponding preischemic baseline counts
(P< .05). In the ATL313-treated IR group, there was a sig-
nificant increase in neutrophils (2.8-fold) over preischemic
counts with no effect on WBCs, lymphocytes, or monocytes
(Figure 1, C). Intergroup analysis of the changes after 2
hours of reperfusion showed no significant difference in
WBC or monocyte counts among the 3 groups. Circulating
neutrophils were significantly elevated in the IR and
IRþATL313 groups versus sham, and lymphocytes were sig-
nificantly lower in the IR group versus the sham and
IRþATL313 groups (Figure 1, C).Pulmonary Function After IR Is Improved by
ATL313
Pulmonary function, evaluated by airway resistance, lung
compliance, and pulmonary arterial pressure, was signifi-
cantly impaired after IR (Figure 2, A). Airway resistance,
lung compliance, and pulmonary arterial pressure were sig-
nificantly improved in ATL313-treated mice after IR. More-
over, airway resistance, lung compliance, and pulmonary
arterial pressure after IR were partially but significantlyery c February 2010
FIGURE 1. Effect of ATL313 on mouse hemodynamics and complete
blood cell counts. A, Heart rate remained stable in vehicle (saline)-treated
mice (n ¼ 4/group). Heart rate was mildly elevated during the first 25 min-
utes after intravenous injection of 3 mg/kg ATL313 compared with vehicle-
treated mice. B, Mean arterial pressure remained stable in vehicle-treated
mice (n ¼ 4/group). Small but insignificant changes in mean arterial pres-
sure occurred after injection of ATL313 during the first 5 minutes. The
time of injection of vehicle and ATL313 is indicated by an arrow. C, Com-
plete blood cell counts after reperfusion are presented as the percentage of
corresponding preoperative baseline counts. Intragroup comparison showed
a 3.5-fold increase in circulating neutrophils in both IR and IRþATL313
groups and a greater than 50% reduction in circulating lymphocytes after
IR. Comparisons among the 3 groups revealed no significant differences
in total white blood cell (WBC) counts. Circulating neutrophils were signif-
icantly elevated in the IR and IRþATL313 groups. Circulating lymphocytes
were significantly reduced in the IR group (*P< .05 vs sham; #P< .05 vs
other groups; n ¼ 5/group).
* RANTES ¼ regulated on activation, normal T expressed and secreted.
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mice compared with IgG control (Figure 2, B). No additional
improvement of lung function occurred after IR whenThe Journal of Thoracic and Caneutrophil- or CD4þ T cell–depleted mice were treated
with ATL313 (Figure 2, B).ATL313 Inhibits Infiltration of T Cells and
Neutrophils
Immunostaining of peripheral lung tissue demonstrated
significant infiltration of CD4þ T cells after IR compared
with sham (Figure 3). ATL313 significantly reduced infiltra-
tion of CD4þT cells after IR (Figure 3). MPO levels in BAL
fluid, used as a biochemical marker of neutrophil infiltration
into alveolar air space, were also significantly increased
after IR and significantly reduced by ATL313 treatment
(Figure 4, A).Lung IR Injury Is Reduced by ATL313
Lung injury after IR was significantly reduced in
ATL313-treated mice as determined by reduced microvas-
cular permeability (via Evans blue content) and pulmonary
edema (wet/dry weight) (Figure 4, A). Lung injury (mea-
sured by microvascular permeability and pulmonary edema)
and neutrophil infiltration (measured by MPO level in BAL
fluid) were significantly reduced after IR in CD4þT cell–de-
pleted and neutrophil-depleted mice compared with IgG
control mice (Figure 4, B). There was no further improve-
ment in lung injury when ATL313 was administered to neu-
trophil-depleted or CD4þT cell–depleted mice (Figure 4, B).Cytokine/Chemokine Expression in ATL313-Treated
Mice
Expression of tumor necrosis factor-alpha (TNF-a), inter-
leukin 17 (IL-17), monocyte chemotactic protein (MCP-1;
CCL2), macrophage inflammatory protein (MIP-1; CCL3),
RANTES* (CCL5), and KC (CXCL1) were significantly in-
creased in BAL fluid after IR, and ATL313 treatment signif-
icantly reduced the expression of each of these cytokines/
chemokines (Figure 5, A). In neutrophil-depleted mice,
expression of TNF-a, MCP-1, MIP-1, and KC remained
elevated after IR; however, IL-17 and RANTES were signif-
icantly reduced compared with IgG control (Figure 5, B).
ATL313 treatment significantly reduced expression of
MIP-1, RANTES, and KC in neutrophil-depleted mice. A
noticeable trend in reduction of TNF-a, IL-17, and MCP-1
production was also observed by ATL313 treatment in
neutrophil-depleted mice (Figure 5, B). The expressions of
IL-17, MCP- 1, MIP-1, RANTES, and KC were all signifi-
cantly reduced in CD4þ T cell–depleted mice versus IgG
control but were not reduced further by ATL313 treatment
(Figure 5, B). A noticeable trend in reduction of TNF-a pro-
duction was observed in CD4þT cell–depleted mice with or
without ATL313 treatment.rdiovascular Surgery c Volume 139, Number 2 477
FIGURE 2. Pulmonary function. A, Airway resistance and pulmonary artery pressure were significantly increased whereas lung compliance was significantly
reduced after ischemia–reperfusion (IR) compared with sham. Pulmonary function was significantly improved after IR by ATL313 treatment (IRþATL313)
(*P<.05 vs sham; #P<.05 vs IR; n¼ 10/group). B, Pulmonary function in antibody-treated mice after IR. Compared with IgG-treated mice, airway resistance
and pulmonary artery pressure were significantly decreased, and lung compliance was significantly increased in neutrophil-depleted (NE dep) and CD4þT
cell–depleted (CD4 dep) mice. No additional protection occurred after ATL313 treatment (ATL). (xP< .05 vs immunoglobulin G; n ¼ 9/group.)
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Using antibody depletion methods, we16 have previously
demonstrated a key role of CD4þT lymphocytes and neutro-
phils in lung IR injury wherein the role of neutrophils as end
effectors of lung injury is secondary to CD4þT cell activa-
tion. In the current study, we also used antibody-depletion
methods to investigate the effects of A2AAR activation on
lung IR injury via its role on CD4þT cells and neutrophils.
We observed that depletion of CD4þ T cells significantly478 The Journal of Thoracic and Cardiovascular Surgattenuated lung injury, neutrophil infiltration, and induction
of proinflammatory cytokines/chemokines after lung IR.
Similarly, neutrophil-depleted mice also displayed signifi-
cantly reduced lung IR injury. The current study showed
that ATL313 exerts significant protection against lung IR in-
jury in control mice but offers no additional protection in
lung function or injury when administered to CD4þT cell–
depleted or neutrophil-depleted mice. Moreover, A2AAR
activation further decreased TNF-a, IL-17, KC, MCP-1,ery c February 2010
FIGURE 3. Pulmonary infiltration of T cells. The average number of
CD4þT cells per high power field (HPF) analysis is shown in the graph,
and examples of immunohistochemical staining are shown for each group
above the corresponding bars. CD4þT cell numbers were significantly in-
creased after ischemia–reperfusion (IR) compared with sham and were sig-
nificantly reduced after IR by ATL313 treatment (IRþATL313). (*P<.05 vs
sham; #P< .05 vs IR; n ¼ 5/group.)
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mice after IR, but did not offer any additional protection in
CD4þ T cell–depleted mice. The attenuation of neutrophil
infiltration by ATL313 likely occurs by 2 means: (1) directly
via activation of A2AAR on neutrophils to prevent activation
and (2) indirectly via activation of A2AAR on CD4þT cells
to attenuate release of potent chemokines. The data from the
current study indicate that the effect of A2AAR activation on
CD4þT cells appears to be more prominent than on neutro-
phils. A2AAR activation on CD4þT cells provides protec-
tion from lung IR injury by attenuating neutrophil
activation and infiltration as demonstrated by the decrease
in MPO levels and significant decreases in IL-17, KC, and
MIP-2 (potent neutrophil chemotactic cytokines). Taken to-
gether, the results demonstrate that the protective effect of
A2AAR activation against lung IR injury is due to its action
on CD4þT cells, as well as neutrophils, and suggest that pro-
tection may be largely due to A2AAR activation on CD4þT
cells.
A2AARs are widely distributed largely in leukocyte cell
populations. The A2AAR agonist, ATL313, binds to re-
combinant mouse adenosine receptor subtypes with Ki
values (nM) as follows: A2A, 2.3< A3, 43< A1, 241<
A2B>1000.
18 We15 have previously used A2AAR knockout
mice to demonstrate that ATL313 reduces lung IR injury in
mice via the specific activation of A2AAR. The identity of
the cell type(s) responsible for mediating the protective ef-
fects of A2AAR activation against lung IR injury remains un-
known and thus was a focus of the current study. A2AARThe Journal of Thoracic and Caactivation mediates immunosuppression by inhibiting the
activation of T lymphocytes and neutrophils, predominantly
by a cyclic adenosine monophosphate–dependent pathway.
The immunosuppressive effects of A2AAR activation have
been confirmed by studies showing that genetic inactivation
of A2AARs increases the intensity and prolongs the duration
of T lymphocyte–dependent cytokine accumulation and tis-
sue damage.19,20 Previous studies in lung injury and other IR
models have demonstrated that A2AARs on bone marrow–
derived cells are required for A2AAR-mediated protection
from reperfusion injury.17,21-23 In lung IR injury, it is postu-
lated that A2AAR activation on CD4þ T lymphocytes and
neutrophils attenuates downstream intercellular signaling
cascade events involving other cell types such as alveolar
macrophages and epithelial and endothelial cells.
A2AAR activation was found to inhibit the redistribution
of circulating lymphocytes after IR as characterized by ele-
vated circulating lymphocytes and reduced lung T cell infil-
tration (Figures 1 and 3). ATL313 was administered shortly
before the onset of reperfusion, and its mild hemodynamic
effect should not have induced any preconditioning effects
against lung IR injury. Activation of A2AAR resulted in re-
duced neutrophil infiltration as demonstrated by reduced
MPO levels (Figure 4). The reduced inflammatory response
as a result of A2AAR activation was also documented by sig-
nificantly reduced levels of CD4þT cell–related cytokines/
chemokines (Figure 5). Activated CD4þT cells are known
to amplify the inflammatory response by producing IL-17,
RANTES, interferon-g, granulocyte-macrophage colony-
stimulating factor, as well as MCP-1, MIP-1, and TNF-a.
The results showed that expression of IL-17, RANTES,
KC, MCP-1, MIP-1, and TNF-bwere significantly increased
after IR. ATL313 significantly abrogated the induction of all
measured cytokines and chemokines. These findings suggest
that ATL313 may act on CD4þT cells to inhibit proinflam-
matory responses after IR.
Our results suggest that both neutrophils and CD4þT cells
are involved in the same cellular signaling pathway that
leads to lung IR injury. Neutrophils are end effectors that
cause lung injury, and injury correlated with BAL MPO
levels (neutrophil infiltration) in our study. CD4þT cell de-
pletion also significantly attenuated MPO levels, thereby im-
plicating a role of the CD4þT cell/neutrophil axis in lung IR
injury. Both T cells and neutrophils express A2AARs, and
activation of A2AARs on both of these cell types has been
shown to inhibit inflammatory responses.13,19 It is plausible
that lack of further protection by ATL313 in neutrophil-de-
pleted mice is simply due to the deficiency of neutrophils;
however, somewhat better protection by ATL313 occurred
in these mice in terms of reduced pulmonary artery pressure
and reduced expression of cytokines. However, in CD4þT
cell–depleted mice, there was no evidence that ATL313 pro-
vided any additional protection, which may be because
CD4þT cell depletion alone is enough to prevent neutrophilrdiovascular Surgery c Volume 139, Number 2 479
FIGURE 4. Neutrophil infiltration and lung injury after reperfusion. Neutrophil infiltration was assessed by measuring myeloperoxidase (MPO) levels in
bronchoalveolar lavage fluid (top). Lung injury was assessed by measuring pulmonary edema (wet/dry weight) (middle) and microvascular leak (Evans
blue content) (bottom). A, Non–antibody-treated mice. B, Antibody-treated mice for IgG-treated control (IgG) and depletion of neutrophils (NE dep) or
CD4þT cells (CD4 dep). All antibody-treated mice underwent lung ischemia–reperfusion (IR). ATL, ATL313 treatment (*P< .05 vs sham; #P< .05 vs
IR, xP< .05 vs IgG control; n ¼ 5/group.)
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phil infiltration by CD4þT cell depletion not only signifies
the role of the CD4þT cell/neutrophil axis as the major sig-
naling pathway, but also implicates CD4þT cells as a pri-
mary target for A2AAR-dependent attenuation of lung IR
injury. Furthermore, the spectrum of changes in cytokines/
chemokines is comparable between ATL313-treated mice
and CD4þ T cell–depleted mice, but not comparable with
neutrophil-depleted mice (Figure 5, B). This suggests that
activation of A2AARs on CD4þT cells is sufficient to inhibit
IR-induced inflammatory responses and reduce lung IR
injury.480 The Journal of Thoracic and Cardiovascular SurgAn interesting observation in this study was that
IR-induced IL-17 production was attenuated by ATL313.
IL-17, produced largely by CD4þnatural killer T cells and
T helper 17 cells, is a key cytokine for the recruitment, acti-
vation, and migration of neutrophils.24 Thus, reduced levels
of KC (a potent neutrophil chemokine) and MPO (ie, neutro-
phil infiltration) in the ATL313-treated groups are likely
secondary to the inactivation of CD4þ T cells. There was
also a significant reduction of IL-17 in neutrophil-depleted
mice that was not as robust as in CD4þ T cell–depleted
mice (Figure 5, B). This supports prior studies suggesting
that neutrophils may also be a source of IL-17.25 However,ery c February 2010
FIGURE 5. Production of cytokines/chemokines after ischemia–reperfusion (IR). Expression of tumor necrosis factor-alpha (TNF- a), interleukin (IL)-17,
monocyte chemotactic protein (MCP-1),macrophage inflammatory protein (MIP-1), regulated on activation, normal T expressed and secreted (RANTES), and
KC were measured in bronchoalveolar lavage fluid after reperfusion. Two separate statistical comparisons are shown: (A) non–antibody-treated mice and (B)
antibody-treated mice for depletion of neutrophils (NE dep) or CD4þT cells (CD4 dep). All antibody-treated animals underwent lung IR. ATL, ATL313
treatment (*P< .05 vs sham and IRþATL; #P< .05 vs IgG control; xP< .05 vs NE dep; n ¼ 5/group).
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Xin the setting of lung IR, the release of IL-17 by neutrophils
appears to be regulated by CD4þT cells via abrogation of
neutrophil chemotactic factors such as KC, IL-17, and
MIP-2. These results further indicate that the anti-inflamma-
tory effect of ATL313 may largely be due to its action on
A2AARs on CD4þT cells.
In summary, the current study aimed to define the cellular
sources whereby A2AAR activation exerts protection from
lung IR injury. Although we found that CD4þT cells medi-
ate neutrophil activation during reperfusion, and the protec-
tive effect of ATL313 is largely due to its action on CD4þT
cells, a role for ATL313 in directly inhibiting neutrophil ac-
tivation or infiltration could not be excluded. Activation of
A2AARs by ATL313 protects the lung against IR injury.
This protection is comparable with that found in CD4þ T
cell–depleted mice. However, no additive effects occur
when ATL313 is applied to CD4þ T cell–depleted mice.
Collectively, these results suggest that CD4þT cells mediate
acute lung IR injury and that the protective effect of A2AAR
activation may be largely due to its actions on CD4þ T
lymphocytes.References
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